These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 21462517)

  • 21. Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events.
    Dalbeth N; Stamp L
    Semin Dial; 2007; 20(5):391-5. PubMed ID: 17897242
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gout in renal allograft recipients according to the pretransplant hyperuricemic status.
    Hernández-Molina G; Cachafeiro-Vilar A; Villa AR; Alberú J; Rull-Gabayet M
    Transplantation; 2008 Dec; 86(11):1543-7. PubMed ID: 19077887
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level.
    Siu YP; Leung KT; Tong MK; Kwan TH
    Am J Kidney Dis; 2006 Jan; 47(1):51-9. PubMed ID: 16377385
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Crystal arthropathies: recognizing and treating "the gouch".
    Quillen DM
    Prim Care; 2010 Dec; 37(4):703-11, v. PubMed ID: 21050952
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Gout].
    Gröbner W; Zöllner N
    Z Rheumatol; 2004 Feb; 63(1):2-9. PubMed ID: 14991273
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hyperuricemia, gout and the metabolic syndrome.
    Puig JG; Martínez MA
    Curr Opin Rheumatol; 2008 Mar; 20(2):187-91. PubMed ID: 18349749
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Trial treatments of hyperuricemia in patients with chronic renal failure. I. Action of benziodarone].
    Richet G; Leroux-Robert C; Podevin R; Amiel C
    Rev Fr Etud Clin Biol; 1966 Apr; 11(4):396-404. PubMed ID: 5944587
    [No Abstract]   [Full Text] [Related]  

  • 28. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout.
    Becker MA; Schumacher HR; Wortmann RL; MacDonald PA; Palo WA; Eustace D; Vernillet L; Joseph-Ridge N
    Arthritis Rheum; 2005 Mar; 52(3):916-23. PubMed ID: 15751090
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Febuxostat: a selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout.
    Bruce SP
    Ann Pharmacother; 2006 Dec; 40(12):2187-94. PubMed ID: 17132810
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Treatment of hyperuricemia in gout and renal insufficiency with benziodarone].
    Richet G; Cottet J; Amiel C; Leroux-Robert C; Podevin R
    Presse Med (1893); 1966 May; 74(24):1247-9. PubMed ID: 5936081
    [No Abstract]   [Full Text] [Related]  

  • 31. Long-term remission from gout associated with fenofibrate therapy.
    Hepburn AL; Kaye SA; Feher MD
    Clin Rheumatol; 2003 Feb; 22(1):73-6. PubMed ID: 12605325
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Treatment of hyperuricemia and gout].
    Gröbner W; Walter-Sack I
    Med Monatsschr Pharm; 2005 May; 28(5):159-64; quiz 165-6. PubMed ID: 15912988
    [No Abstract]   [Full Text] [Related]  

  • 33. The effect of mild hyperuricemia on urinary transforming growth factor beta and the progression of chronic kidney disease.
    Talaat KM; el-Sheikh AR
    Am J Nephrol; 2007; 27(5):435-40. PubMed ID: 17622758
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PEG-uricase in the management of treatment-resistant gout and hyperuricemia.
    Sherman MR; Saifer MG; Perez-Ruiz F
    Adv Drug Deliv Rev; 2008 Jan; 60(1):59-68. PubMed ID: 17826865
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Crystal ball gazing: new therapeutic targets for hyperuricaemia and gout.
    Dalbeth N; Merriman T
    Rheumatology (Oxford); 2009 Mar; 48(3):222-6. PubMed ID: 19109320
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Emerging therapies in the long-term management of hyperuricaemia and gout.
    Stamp LK; O'Donnell JL; Chapman PT
    Intern Med J; 2007 Apr; 37(4):258-66. PubMed ID: 17388867
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Understanding treatments for gout.
    Cannella AC; Mikuls TR
    Am J Manag Care; 2005 Nov; 11(15 Suppl):S451-8; quiz S465-8. PubMed ID: 16300459
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.
    Becker MA; Schumacher HR; MacDonald PA; Lloyd E; Lademacher C
    J Rheumatol; 2009 Jun; 36(6):1273-82. PubMed ID: 19286847
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Benziodarone in hyperuricemia due to renal insufficiency].
    Boine L
    Minerva Med; 1973 Jan; 64(4):157-9. PubMed ID: 4568713
    [No Abstract]   [Full Text] [Related]  

  • 40. Hyperuricemia, gout, and related comorbidities: cause and effect on a two-way street.
    Karis E; Crittenden DB; Pillinger MH
    South Med J; 2014 Apr; 107(4):235-41. PubMed ID: 24937517
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.